Biorestorative Therapies Stock Performance
| BRTX Stock | USD 1.53 0.05 3.38% |
BioRestorative Therapies has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 1.77, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, BioRestorative Therapies will likely underperform. BioRestorative Therapies right now shows a risk of 4.17%. Please confirm BioRestorative Therapies jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if BioRestorative Therapies will be following its price patterns.
Risk-Adjusted Performance
1 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in BioRestorative Therapies are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly strong basic indicators, BioRestorative Therapies is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
Last Split Factor 1:4000 | Last Split Date 2021-10-27 |
1 | BioRestorative Therapies Hits New 1-Year High at 1.50 - MarketBeat | 09/11/2024 |
2 | BioRestorative Therapies IFATS 2024 Presentation to Feature ThermoStem Platforms Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Dr... | 09/19/2024 |
3 | Acquisition by Lance Alstodt of 100 shares of BioRestorative Therapies at 2.99 subject to Rule 16b-3 | 09/27/2024 |
4 | BioRestorative Therapies, Inc. Sees Large Increase in Short Interest | 10/01/2024 |
5 | BioRestorative Therapies Reaches New 12-Month High Should You Buy | 10/17/2024 |
6 | Disposition of 1112 shares by Broadrick Dale of BioRestorative Therapies at 1.58 subject to Rule 16b-3 | 10/28/2024 |
7 | Broadrick Dale reduces stake in BioRestorative Therapies, Inc. with 1,756 sale | 11/05/2024 |
8 | Acquisition by Francisco Silva of 2816 shares of BioRestorative Therapies at 3.213 subject to Rule 16b-3 | 11/07/2024 |
9 | Acquisition by Broadrick Dale of 100 shares of BioRestorative Therapies at 2.78 subject to Rule 16b-3 | 11/08/2024 |
10 | BioRestorative Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update | 11/12/2024 |
11 | BioRestorative Therapies Issues Quarterly Earnings Results, Beats Estimates By 0.22 EPS | 11/14/2024 |
12 | BioRestorative Therapies, Inc. Q3 2024 Earnings Call Transcript | 11/15/2024 |
| Begin Period Cash Flow | 1.7 M |
BioRestorative |
BioRestorative Therapies Relative Risk vs. Return Landscape
If you would invest 155.00 in BioRestorative Therapies on September 2, 2024 and sell it today you would lose (2.00) from holding BioRestorative Therapies or give up 1.29% of portfolio value over 90 days. BioRestorative Therapies is currently generating 0.0634% in daily expected returns and assumes 4.165% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than BioRestorative, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BioRestorative Therapies Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioRestorative Therapies' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as BioRestorative Therapies, and traders can use it to determine the average amount a BioRestorative Therapies' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0152
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | BRTX | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.17 actual daily | 37 63% of assets are more volatile |
Expected Return
| 0.06 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average BioRestorative Therapies is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioRestorative Therapies by adding it to a well-diversified portfolio.
BioRestorative Therapies Fundamentals Growth
BioRestorative Stock prices reflect investors' perceptions of the future prospects and financial health of BioRestorative Therapies, and BioRestorative Therapies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioRestorative Stock performance.
| Return On Equity | -0.17 | ||||
| Return On Asset | -0.53 | ||||
| Operating Margin | (9.79) % | ||||
| Current Valuation | (2.44 M) | ||||
| Shares Outstanding | 6.92 M | ||||
| Price To Earning | (1.79) X | ||||
| Price To Book | 1.06 X | ||||
| Price To Sales | 28.08 X | ||||
| Revenue | 145.8 K | ||||
| Gross Profit | 119.8 K | ||||
| EBITDA | (15.06 M) | ||||
| Net Income | (10.42 M) | ||||
| Cash And Equivalents | 17.93 M | ||||
| Cash Per Share | 4.92 X | ||||
| Total Debt | 162.32 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 29.47 X | ||||
| Book Value Per Share | 1.44 X | ||||
| Cash Flow From Operations | (6.43 M) | ||||
| Earnings Per Share | (2.38) X | ||||
| Market Capitalization | 10.59 M | ||||
| Total Asset | 12.61 M | ||||
| Retained Earnings | (146.7 M) | ||||
| Working Capital | 8.78 M | ||||
| Current Asset | 289.28 K | ||||
| Current Liabilities | 5.61 M | ||||
About BioRestorative Therapies Performance
Evaluating BioRestorative Therapies' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if BioRestorative Therapies has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BioRestorative Therapies has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.88) | (0.92) | |
| Return On Capital Employed | (1.52) | (1.45) | |
| Return On Assets | (0.83) | (0.87) | |
| Return On Equity | (1.04) | (0.99) |
Things to note about BioRestorative Therapies performance evaluation
Checking the ongoing alerts about BioRestorative Therapies for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BioRestorative Therapies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioRestorative Therapies may become a speculative penny stock | |
| BioRestorative Therapies had very high historical volatility over the last 90 days | |
| BioRestorative Therapies has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 145.8 K. Net Loss for the year was (10.42 M) with profit before overhead, payroll, taxes, and interest of 119.8 K. | |
| BioRestorative Therapies currently holds about 17.93 M in cash with (6.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.92, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| BioRestorative Therapies has a poor financial position based on the latest SEC disclosures | |
| Roughly 26.0% of the company shares are held by company insiders | |
| Latest headline from insidermonkey.com: BioRestorative Therapies, Inc. Q3 2024 Earnings Call Transcript |
- Analyzing BioRestorative Therapies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioRestorative Therapies' stock is overvalued or undervalued compared to its peers.
- Examining BioRestorative Therapies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioRestorative Therapies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioRestorative Therapies' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioRestorative Therapies' stock. These opinions can provide insight into BioRestorative Therapies' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for BioRestorative Stock Analysis
When running BioRestorative Therapies' price analysis, check to measure BioRestorative Therapies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioRestorative Therapies is operating at the current time. Most of BioRestorative Therapies' value examination focuses on studying past and present price action to predict the probability of BioRestorative Therapies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioRestorative Therapies' price. Additionally, you may evaluate how the addition of BioRestorative Therapies to your portfolios can decrease your overall portfolio volatility.